A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation
- 387 Downloads
Filgrastim-sndz (Zarxio®) was approved by the FDA in March 2015 as a biosimilar product of its reference product, filgrastim (Neupogen®) for all five indications. The NCCN Clinical Practice Guidelines has incorporated filgrastim-sndz into its recommendations as a category 1 recommendation for use in settings of febrile neutropenia, myelosuppressive chemotherapy administration, and post-hematopoietic stem cell transplant (HSCT). As a cost-saving initiative, our institution switched from filgrastim to filgrastim-sndz for all indications starting in March 2016. The purpose of this study was to assess for any difference in clinical or safety outcomes between filgrastim and filgrastim-sndz. This is an IRB-approved, single institution, 1-year retrospective chart review (September 2015 to August 2016) conducted in hospitalized adults who received either filgrastim or filgrastim-sndz either for prophylaxis of chemotherapy-induced myelosuppression or for neutrophil recovery after autologous HSCT. Our data showed no differences in duration of G-CSF therapy (7.96 vs. 8.5 days, P = 0.36), white blood count (WBC) (8.99 vs. 8.04, P = 0.28), absolute neutrophil count (ANC) (7.62 vs. 6.91 × 109/L, P = 0.36) at the time of granulocyte-colony stimulating factor (G-CSF) discontinuation, or safety of filgrastim and filgrastim-sndz. The efficacy and safety of filgrastim and filgrastim-sndz were similar for prophylaxis of chemotherapy-induced neutropenia and neutrophil recovery post-autologous HSCT.
KeywordsFilgrastim Filgrastim-sndz Biosimilar Zarxio Neupogen
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Maschmeyer G, Rolston K. Myeloid growth factors. Infections in Hematology. Springer Berlin Heidelberg: 2015Google Scholar
- 4.National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: myeloid growth factors. Version 1.2017. NCCN.org
- 10.Awad M et al (2017) Zarxio (filgrastim-sndz): the first biosimilar approved by the FDA. PT 42:19–23Google Scholar
- 11.Blackwell K et al (2015) Comparison of EP2006, a filgrastim biosimilar, to the reference: phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 26(9):1948–1953. https://doi.org/10.1093/annonc/mdv281 CrossRefPubMedPubMedCentralGoogle Scholar